[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 819
Citations 0
Correction
September 25, 2018

Omission of Conflicts of Interest

JAMA. 2018;320(12):1288. doi:10.1001/jama.2018.13704

In the Letter to the Editor entitled “Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain,” published in the August 7, 2018, issue of JAMA,1 conflict of interest disclosures were omitted. Dr Singh’s full disclosure should have read “Dr Singh reported receiving grant funding from Takeda and Savient and consulting fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, Allergan, WebMD, UBM, Medscape, Fidia, and the American College of Rheumatology; serving as principal investigator for an investigator-initiated study funded by Horizon Pharma through a grant to DINORA, a 501(c)(3) entity; being a member of the executive committee of Outcome Measures in Rheumatology, a member of the American College of Rheumatology’s (ACR) annual meeting planning committee, the Veterans Affairs Rheumatology field advisory committee, chair of the ACR Meet the Professor Workshop and Study Group subcommittee, and editor and director of the University of Alabama at Birmingham Cochrane Musculoskeletal Group Satellite Center on network meta-analysis.” This article was corrected online.

References
1.
Singh  JA, Curtis  JR, Saag  KG.  Opioids vs nonopioids for chronic back, hip, or knee pain [letter].  JAMA. 2018;320(5):508. doi:10.1001/jama.2018.6937PubMedGoogle ScholarCrossref
×